Our results with pre-treatment tumour samples showed that the number of NK-cells was low and showed only a tendency towards better prognosis suggesting that NK-cell infiltration is not a good predictive marker for trastuzumab response in clinical tumour samples of HER2 positive breast cancer. Here, ERBB2 is linked to breast carcinoma.